Weight loss

In this randomized placebo-controlled trial of 2539 adults with obesity or overweight (BMI ≥30 or ≥27 kg/m² with complications), participants achieving up to 20.9% weight reduction over 72 weeks showed serum uric acid reductions of -0.69 to -0.95 mg/dL compared to -0.18 mg/dL with placebo (all P <.001). Mediation analysis demonstrated that weight reduction explained 72.7% of the serum uric acid reduction. The uric acid lowering effect was consistent regardless of baseline BMI values (P = .362) or baseline uric acid quartiles (P = .610), indicating weight loss benefits gout risk across all starting weights and uric acid levels.

View Source →

In this community screening of 56 participants, 42.9% (24 individuals) were identified as being at elevated risk for gout due to being overweight or obese. Notably, this same proportion (42.9%, 24 participants) showed elevated uric acid levels on laboratory testing. The study identified obesity as one of six key modifiable risk factors for gout arthritis development.

View Source →

In this 3-year prospective cohort study of 1,164 adults with gout (mean age 65.6 ± 12.5 years, 84% male), latent class growth analysis identified six distinct flare trajectory classes. The 'frequent and persistent' trajectory class (n=95) had the highest proportion of members classified as obese compared to other trajectory classes. This class experienced consistently high flare frequency throughout the 36-month follow-up period, while the 'infrequent' class (n=349) showed better outcomes.

View Source →

In this 3-year prospective cohort study of 1,164 gout patients (mean age 65.6 ± 12.5 years, 84% male), latent class growth analysis identified six distinct flare trajectories. The 'frequent and persistent' class (n=95) had the highest proportion of members classified as obese compared to other trajectory classes. This class experienced the worst outcomes with continuous high flare frequency over 36 months. The 'infrequent' class (n=349), which had better outcomes, showed lower obesity rates. These findings from 20 general practices suggest obesity is a modifiable risk factor associated with poor gout flare trajectories.

View Source →

The 2020 ACR Gout Guideline includes weight management among lifestyle recommendations, developed using GRADE methodology rating certainty of evidence. The systematic review addressed 9 PICO questions specific to lifestyle strategies in patients with gout. The expert panel, voting panel, and patient panel all contributed to the final recommendations emphasizing actionable lifestyle modifications for comprehensive gout management.

View Source →

The systematic review examined BMI, waist and chest circumference, waist-to-hip ratio, and weight change as risk factors for incident gout across 33 cohort studies. Among the 20 studies (60.6%) directly comparing risk factors by gender, adiposity measures showed similar risk increases in both men and women. These anthropometric factors were consistently associated with gout development in cohort studies from general population and primary care settings searched through March 2019.

View Source →

The British Society for Rheumatology guideline (Level of Evidence III, Strength of Recommendation 92%) recommends that in overweight patients, dietary modification to achieve a gradual reduction in body weight and subsequent maintenance should be encouraged. Diet and exercise should be discussed with all patients with gout. The guideline emphasizes individualized management taking into account comorbidities and concurrent medications.

View Source →

This comprehensive umbrella review analyzed 57 articles with 144 meta-analyses of observational studies examining 76 unique outcomes, plus Mendelian randomisation studies confirming the causal link between high serum uric acid and gout. Five associations were classified as highly suggestive in observational meta-analyses, including heart failure, hypertension, diabetes, chronic kidney disease, and coronary heart disease mortality—conditions often clustering with obesity. Weight management addresses the metabolic factors contributing to elevated serum uric acid.

View Source →

Developed through systematic literature review and expert consensus of 78 international rheumatologists from 14 countries, the 3e Initiative guidelines achieved agreement scores of 8.1-9.2 (mean 8.7/10). Ten recommendations were produced covering diagnosis and management, with six addressing various management aspects. Two independent reviewers extracted data and assessed risk of bias from searched databases including Medline, Embase, and Cochrane CENTRAL. The recommendations emphasize addressing modifiable cardiovascular and metabolic risk factors, which includes weight management for overweight or obese gout patients.

View Source →

This clinical guideline was formulated by 78 rheumatologists from 14 countries using systematic literature review methodology. Searches included Medline, Embase, Cochrane CENTRAL, and recent EULAR/ACR meeting abstracts (2010-2011). Each recommendation was graded according to level of evidence, with lifestyle modifications including weight management incorporated into the six management-focused recommendations. The expert panel demonstrated strong consensus with agreement scores ranging from 8.1 to 9.2 (mean 8.7 on a 10-point scale), validating weight loss as an evidence-supported intervention.

View Source →

The SIR guideline development process involved systematic evidence collection on non-pharmacological interventions for gout. A Delphi consensus approach among the multidisciplinary panel identified priority research queries, including lifestyle modifications. The 12 original EULAR propositions were translated, adapted, and updated based on systematic review findings. The guideline explicitly addresses diet's role in gout management, and weight management is integral to dietary intervention. RCT data on lifestyle interventions were evaluated where available, with recommendation strength measured using standardized EULAR methodology including ordinal and visual analogue scales.

View Source →

This case-control study of 98 gout cases and 98 controls demonstrated that central obesity was a significant risk factor for gouty arthritis with an odds ratio of 3.04 (95% CI: 1.66-5.55). The confidence interval entirely above 1.0 confirms a statistically significant threefold increased risk of gout among those with central obesity compared to those without.

View Source →

The clinical guideline identifies obesity, along with hypertension, metabolic syndrome, type 2 diabetes mellitus, and chronic kidney disease, as comorbidities that promote hyperuricemia and have contributed to the increased prevalence of gout over recent decades. The guideline explicitly recommends patient education on lifestyle modifications as a core therapeutic measure, alongside diet education and management of comorbidities, to help achieve serum urate targets below 6 mg/dl.

View Source →

This systematic review identified advice to lose weight as a preventive intervention for gout in patients with prior acute episodes. The review searched multiple databases including Medline, Embase, and The Cochrane Library through June 2008, finding 21 systematic reviews, RCTs, or observational studies meeting inclusion criteria. Given that gout affects 5% of men and 1% of women, with recurrence rates up to 80% within 3 years, weight management represents an important modifiable risk factor. GRADE evaluation assessed the quality of evidence for this and other lifestyle interventions.

View Source →